Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model

Clinical and Experimental Immunology

Volumn 116, Issue 3, 1999, Pages 462-467

  Palermo, M S ^a   Alves Rosa, M F ^a   Van Rooijen, N ^b   Isturiz, Martín A ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Haemolytic uraemic syndrome; Lipopolysaccharide; Macrophages; Shiga toxin

Indexed keywords

CLODRONIC ACID; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; SHIGA TOXIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DEPLETION; FEMALE; HEMOLYTIC UREMIC SYNDROME; LIVER; MACROPHAGE FUNCTION; MALE; MONONUCLEAR PHAGOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPLEEN; SURVIVAL;

ANIMALS; BACTERIAL TOXINS; CLODRONIC ACID; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LIPOPOLYSACCHARIDES; LIPOSOMES; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; SHIGA TOXINS; SPLEEN;

EID: 0033030437     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00925.x     Document Type: Article

References (44)

1. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of hemolytic-uraemic syndrome associated with faecal verotoxin and cytotoxin producing Escherichia coli in stools. Lancet 1983; 1:619-20.
2. Riley LW, Remis RS, Helgerson SD et al. Hemorrhagic colitis associated with a rare Escherichia coli O157:H7 serotype. N Engl J Med 1983; 308:681-5.
3. Kaplan BS, Cleary TG, Obrig TG. Recent advances in understanding the pathogenesis of the hemolytic uremic syndrome. Pediatr Nephrol 1990; 4:276-83.
4. Van de Kar NCAJ, Monnens LA, Karmali MA, van Hinsbergh VWM. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotryaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992; 80:2755-64.
5. Louise CB, Obrig TG. Shiga toxin associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun 1992; 60:1536-43.
6. Louise CB, Obrig TG. Shiga toxin associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1β, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 1991; 59:4173-9.
7. Barret TJ, Potter ME, Wachsmuth IK. Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect Immun 1989; 57:3434-7.
8. Harel Y, Silva M, Giroir B, Weinberg A, Cleary TB, Beutler B. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by Shiga-like toxin. J Clin Invest 1993; 92:2110-6.
9. Karpman D, Connell H, Svensson M, Scheutz F, Alm P, Svanborg C. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997; 175:611-20.
10. Van Rooijen N. The liposome mediated macrophage "suicide" technique. J Immunol Methods 1989; 124:1-6.
11. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174:83-93.
12. Van Rooijen N, Van Nieuwnegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome encapsulated dichloromethytene-diphosphonate. An enzyme histochemical study. Cell Tissue Res 1984; 238:355-8.
13. Fleish H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Handbook Exp Pharmacol 1988; 83:441-66.
14. Dunn CJ, Galinet LA, Wu H et al. Demonstration of novel anti-arthritic and antiinflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993; 266:1691-8.
15. Monkkonen J, Pennanen N, Lapinjoki S, Urti A. Clodronate (dichloromethylene biphosphonate) inhibits LPS stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 1994; 54:229-34.
16. Pennanen N, Lapinjoki S, Urti A, Monkkonen J. Effect of liposomal and free biphosphonates on the IL-1β, IL-6, and TNF-α secretion from RAW 264 cells in vitro. Pharmaceut Res 1995; 12:912-22.
17. Van Rooijen N, Sanders A, Van den Berg T. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996; 193:93-99.
18. National Institutes of Health. Guide for the care and use of laboratory animals. NIH publication no. 85-23. Bethesda, MD: National Institutes of Health, 1985.
19. Duner KI. A new kinetic single stage Limulus amoebocyte lysate method for the detection of endotoxin in water and plasma. J Biochem Biophys Methods 1993; 26:131-42.
20. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151:775-82.
21. Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985; 228:149-54.
22. Palermo MS, Giordano M, Isturiz MA. Effect of cyclophosphamide on the clearance of IgG-sensitized red cells in mice. Clin Immunol Immunopathol 1991; 58:343-51.
23. Palermo MS, Alves Rosa F, Fernández Alonso G, Isturiz MA. Fcγ receptor-dependent clearance is enhanced following lipopolysaccharide in vivo treatment. Immunol 1997; 92:536-43.
24. Raveteh JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16:421-32.
25. Salkowsky CA, Neta R, Wynn TA, Strassmann G, van Rooijen N, Vogel SN. Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection. J Immunol 1995; 155:3168-79.
26. Fontaine A, Arondel J, Sansonetti PJ. Role of Shiga toxin in the pathogenesis of bacillary dysentery studied by using a Tox negative mutant of Shigella dysenteriae I. Infect Immun 1988; 56:3099-109.
27. Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1β enhancement of shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993; 61:3886-91.
28. Kosler F, Boonpucknavig V, Suiaoho S, Gilman R, RahamanM. Renal histopathology in the hemolytic uremic syndrome following shigellosis. Clin Nephrol 1984; 21:126-33.
29. Koster F, Levin J, Walker L et al. Hemolytic uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Eng J Med 1978; 298:927-33.
30. Tesh VL, Ramegowda B, Samuel JE. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 1994; 62:5085-94.
31. Barret TJ, Potter ME, Strockbine NA. Evidence for participation of the macrophage in Shiga like toxin-II induced lethality in mice. Microb Pathog 1990; 9:95-103.
32. Tipping PG, Leong TW, Holdsworth SR. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest 1991; 65:272-9.
33. Baud L, Oudinet JP, Bens M, Noe L, Peraldi MN, Rondeua E, Etienne J, Ardaillou R. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 1989; 35:1111-8.
34. Hruby ZW, Lowry RP. Spontaneous release of tumor necrosis factor alpha by isolated renal glomeruli and cultured glomerular mesangial cells. Clin Immunol Immunophatol 1991; 59:156-64.
35. Albrecht H, Schook LB, Jongeneel CV. Nuclear migration of NF-κB correlates with TNF-αmRNA accumulation. J Inflamm 1995; 45:64-71.
36. Economou J, MC Bride WH, Essner R, Rhoades R, Golub S, Holmes HC. Tumor necrosis factor production by IL-2 activated macrophages in vitro and in vivo. Immunol 1989; 67:514-9.
37. Cannistra S, Rambaldi A, Spriggs DR, Herrmann F, Kufe D, Griffin JD. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest 1987; 79:1720-8.
38. Warren MK, Ralph P. Macrophage growth factor CSF-I stimulates human monocyte production of interferon, tumor necrosis factor, and colony stimulating activity. J Immunol 1986; 137:2281-5.
39. Schook LB, Albrecht H, Gallay P, Jongeneel CV. Cytokine regulation of TNF-αmRNA and protein production by unprimed macrophages from C57B1/6 and NZW mice. J Leuk Biol 1994; 56:514-20.
40. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four (B-like motifs and of constitutive and inducible form of NF-κB. Mol Cell Biol 1990; 10:1498-506.
41. Qian Q, Jutila MA, van Rooijen N, Cutler JE. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol 1994; 152:5000-8.
42. Van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leuk Biol 1989; 45:97-104.
43. Bogers WMJM, Stad RK, Janssen DJ, van Rooijen N, van Es LA, Daha MR. Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells. Clin Exp Immunol 1991; 86:328-33.
44. Van Rooijen N, Sanders A. Elimination, blocking, and activation of macrophages: three of a kind? J Leuk Biol 1997; 62:1-8.